Tunisia
Mubasher TV
 Contact Us Advertising   العربية
Tunisia
BDT Closed
09 July 12:06 AM

Transaction in Own Shares

Hikma HIK -6.11% 19.20 -1.25

Published: Jun 23, 2026 09:00:07 AM
Sequence No.: 42
ISIN: US4312882081

HIKMA PHARMACEUTICALS PLC

 

TRANSACTIONS IN OWN SHARES

 

Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) (the ''Company'') announces that, during the period from 15 June 2026 to 19 June 2026 (inclusive) (the ''Disclosure Period''), it purchased the following number of its ordinary shares of 10 pence each through J.P. Morgan Securities plc as part of the second tranche (which commenced on 27 May 2026) of its $250 million share repurchase programme announced on 26 February 2026 (the ''Buyback Programme'').

 

Date within Disclosure Period

Trading Venue

Aggregate number of ordinary shares repurchased

Lowest price paid(pence)

Highest price paid (pence)

Volume-weighted average price (pence)

15 June 2026

XLON

102,806

1,472.0000

1,483.0000

1,475.8276

16 June 2026

BATE

38,351

1,462.0000

1,468.0000

1,464.8009

16 June 2026

XLON

132,649

1,460.0000

1,480.0000

1,467.6961

17 June 2026

AQXE

9,824

1,460.0000

1,463.0000

1,462.6856

17 June 2026

BATE

93,467

1,459.0000

1,468.0000

1,465.8490

17 June 2026

CHIX

16,219

1,459.0000

1,463.0000

1,462.6315

17 June 2026

TRQX

6,392

1,459.0000

1,463.0000

1,462.7829

17 June 2026

XLON

117,451

1,459.0000

1,477.0000

1,466.3286

18 June 2026

AQXE

11,353

1,449.0000

1,460.0000

1,455.2915

18 June 2026

BATE

100,215

1,446.0000

1,461.0000

1,454.0436

18 June 2026

CHIX

18,683

1,449.0000

1,460.0000

1,455.2551

18 June 2026

TRQX

7,521

1,451.0000

1,460.0000

1,455.6092

18 June 2026

XLON

128,723

1,446.0000

1,461.0000

1,453.8950

19 June 2026

AQXE

11,965

1,460.0000

1,474.0000

1,467.5480

19 June 2026

BATE

103,654

1,456.0000

1,474.0000

1,467.6821

19 June 2026

CHIX

19,700

1,454.0000

1,474.0000

1,467.4343

19 June 2026

TRQX

7,975

1,460.0000

1,474.0000

1,467.4392

19 June 2026

XLON

139,194

1,455.0000

1,476.0000

1,467.3681

 

The Company intends to cancel the repurchased shares.

 

Since the launch of the Buyback Programme on 26 February 2026, the Company has purchased a total of 9,631,818 ordinary shares at a total cost of £130,317,376.42.

 

The Company holds 12,833,233 of its ordinary shares in treasury.

 

Following the settlement of the above transactions and cancellation of the repurchased shares, the Company will have 212,254,635 ordinary shares in issue (excluding treasury shares) and the total number of voting rights in the Company will therefore be 212,254,635.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), a schedule of individual trades made by J.P. Morgan Securities plc as principal during the Disclosure Period pursuant to the Buyback Programme is available at the link below.

 

 

Enquiries:

 

Hikma Pharmaceuticals PLC               

 

Susan Ringdal

 

EVP, Strategic Planning and Global Affairs +44 (0) 20 7399 2760 / +44 (0) 7776 477050

 

Guy Featherstone

 

Director, Investor Relations +44 (0) 20 3892 4389 / +44 (0) 7795 896738

 

Attachment(s)

Schedule of individual trades made by J.P. Morgan Securities plc as principal during the Disclosure Period pursuant to the Buyback Programme

 

Comments